A recent Newsday article shines a spotlight on the growing number of Long Island residents turning to GLP-1 medications like Wegovy and Ozempic as part of their weight-loss journey. The article features a range of personal success stories from local patients and includes expert commentary from Dr. Michael Kaplan, founder of the Long Island Weight Loss Institute (LIWLI).
As one of the first physicians in the region to adopt GLP-1-based treatments, Dr. Kaplan has seen firsthand how these medications can change lives—not just by reducing weight, but by improving overall health and well-being.
“What we’re seeing is not just weight loss, but metabolic recovery,” Dr. Kaplan explained in the article. “It’s about reclaiming health—especially for patients who’ve struggled with obesity for years.”
The Newsday piece notes that while the results are often dramatic, many patients face challenges related to insurance coverage and out-of-pocket costs. Despite these hurdles, interest in medications like Ozempic and Wegovy continues to grow—especially when paired with professional medical guidance, nutritional coaching, and long-term support.
Dr. Kaplan emphasized that LIWLI’s approach goes beyond prescribing medication. The Institute’s programs are designed to address the full picture of a patient’s health through customized care plans, lab testing, and ongoing clinical monitoring.
“We believe everyone deserves the chance to feel better, look better, and live longer,” Kaplan said.
As more people turn to medically supervised weight loss, the role of experienced physicians like Dr. Kaplan becomes increasingly vital. The Newsday article positions LIWLI as a trusted resource for those navigating the complex world of GLP-1 treatments and long-term health management.
Read the full story at newsday.com.